Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24036282 | 0.94 | MAPT (0.31) | MAPTTP53 | |
| SCHEMBL24853795 | 0.94 | MAPT (0.31) | MAPTTP53 | |
| SCHEMBL24035352 | 0.94 | MAPT (0.31) | MAPTTP53 | |
| SCHEMBL26734737 | 0.94 | HDAC4 (0.32) | CNR2CNR1MAPTTP53KMT2A | |
| SCHEMBL29065115 | 0.90 | MAPT (0.30) | MAPT | |
| SCHEMBL26735300 | 0.90 | CNR1 (0.32) | CNR2CNR1MAPTKMT2A | |
| SCHEMBL24035963 | 0.90 | CNR2 (0.31) | CNR2CNR1MAPTTP53 | |
| SCHEMBL24036223 | 0.89 | KCNH2 (0.32) | MAPT | |
| SCHEMBL24035886 | 0.88 | LMNA (0.34) | CNR1MAPTTP53KMT2A | |
| SCHEMBL24036286 | 0.88 | LMNA (0.34) | CNR1MAPTTP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2021231474-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | CNR2 4771/4885CNR1 4652/4885MAPT 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.